|
24 Nov 2020 |
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients
|
|
24 Nov 2020 |
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
|
|
23 Nov 2020 |
Catamaran Bio Launches with $42 Million Financing to Develop Off the Shelf CAR-NK Cell Therapies to Treat Solid Tumors
|
|
22 Nov 2020 |
DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting
|
|
20 Nov 2020 |
INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
|
|
20 Nov 2020 |
Glycostem initiates phase I/IIa (pivotal) trial to evaluate the safety and efficacy of oNKord® in patients with Acute Myeloid Leukemia (AML)
|
|
20 Nov 2020 |
uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
|
|
20 Nov 2020 |
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
|
|
19 Nov 2020 |
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)
|
|
19 Nov 2020 |
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
|
|
19 Nov 2020 |
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
|
|
19 Nov 2020 |
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
|
|
19 Nov 2020 |
Bristol secures £45M to advance gene therapy treatment of chronic kidney diseases
|
|
19 Nov 2020 |
Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary and secondary liver cancer
|
|
18 Nov 2020 |
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma
|
|
18 Nov 2020 |
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
|
|
17 Nov 2020 |
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020
|
|
16 Nov 2020 |
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
|
|
16 Nov 2020 |
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
|
|
15 Nov 2020 |
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
|
13 Nov 2020 |
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
|
|
13 Nov 2020 |
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
|
|
13 Nov 2020 |
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
|
|
13 Nov 2020 |
MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic
|
|
13 Nov 2020 |
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
|
